Afatinib, a second-generation EGFR-TKI, was previously shown to be effective in NSCLC patients.[2] However, the efficacy of another second-generation EGFR-TKI, dacomitinib, in the treatment of rare EGFR mutations has not been demonstrated. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.